Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 43

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 43
---
 of ZL-1310, a potential first-in-class and best-in-class DLL3-targeted antibody drug conjugate (“ADC”) for the treatment of extensive stage small cell lung cancer (“SCLC”), and promising pre-clinical data for ZL-1503, our internally discovered and developed IL-13/IL-31R bispecific antibody for atopic dermatitis. For our late-stage regional pipeline, we had positive data readouts, including for KarXT in

<div align='center'>-31-</div>

schizophrenia, and we completed enrollment for the second Phase III study of bemarituzumab for the treatment of gastric cancer. With this robust pipeline, we expect to launch several new products or additional indications for existing commercial products in the next two to three years.

• Growing and Strengthening Our Pipeline: We continue to build our global portfolio through our internal discovery efforts and to expand our portfolio through synergistic regional and global collaboration efforts and corporate development activities. For example, we entered into a strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN ADC platform for the development of ZL-6201, a novel potential first-in-class LRRC15 ADC consisting of an antibody discovered by Zai Lab, for the treatment of certain solid tumors and a strategic collaboration with Vertex Pharmaceuticals Inc. for the license of povetacicept, a potential best-in-class treatment for Immunoglobulin A nephropathy (“IgAN”) and other B-cell mediated diseases, in mainland China, Hong Kong, Macau, Taiwan, and Singapore.

For a summary of our corporate performance goals, and our performance with respect to these goals, see Corporate Performance Goals and Results .

#### 2024 Say-on-Pay Vote and Shareholder Engagement
The Compensation Committee remains committed to maintaining an open dialogue with the investor community. We regularly engage with our shareholders to discuss business topics, seek feedback on our performance, and address matters such as executive compensation. In line with our commitment to ongoing dialogue and responsiveness to investor feedback, we continued our shareholder engagement efforts following our most recent say-on-pay vote, which received “FOR” votes equal to 67.7% of the votes cast in 2024.

Throughout 2024, our Board of Directors and management made themselves available to engage with shareholders, offering the flexibility to meet jointly or separately based on investor preferences. We initiated contact with shareholders representing approximately 52